Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Timolol is a non-selective beta adrenergic blocker (beta blocker) used to treat several cardiovascular and ophthalmic conditions. Orally, it is prescribed for hypertension (high blood pressure), prevention of migraine headaches, and to improve survival after a heart attack by relaxing blood vessels and slowing the heart rate[1][5][7]. As an ophthalmic solution (eye drops), timolol is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension[2][3][4]. Its mechanism of action involves blocking both beta-1 and beta-2 adrenergic receptors, reducing aqueous humor production in the eye and decreasing cardiac output systemically. Timolol was first approved by the FDA in 1978, is available as a generic medication, and appears on the World Health Organization's List of Essential Medicines[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on timolol.